Ani Pharmaceuticals Inc. (ANIP)
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
ANIP Stock Rises 7% in a Week: Here's What You Should Know
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance
ANI Pharmaceuticals delivered robust 2025 results and issued bullish 2026 guidance, targeting $1.055–$1.115 billion in revenues, up 60% year-over-year. Purified Cortrophin Gel remains the primary growth engine, projected to reach $540–$575 million in 2026, supported by a 90-person commercial expansion and a pivotal Phase 4 trial. ANIP's valuation is compelling at 11.2x forward P/E, a 43% sector discount, with strong liquidity ($285 million cash) and no cash burn anticipated.
Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength?
ANI (ANIP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
